Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Medexus Pharmaceuticals Inc (MDP.TO)

Medexus Pharmaceuticals Inc (MDP.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 49,881
  • Shares Outstanding, K 19,953
  • Annual Sales, $ 76,701 K
  • Annual Income, $ -2,879 K
  • 60-Month Beta 1.56
  • Price/Sales 0.49
  • Price/Cash Flow N/A
  • Price/Book 2.16
Trade MDP.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.15
  • Most Recent Earnings -0.27 on N/A
  • Next Earnings Date 08/15/22
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Drug Specialty & Generic

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.17
  • Number of Estimates 3
  • High Estimate -0.13
  • Low Estimate -0.20
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +73.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.59 +85.53%
on 07/14/22
3.00 -1.67%
on 08/09/22
+1.03 (+53.65%)
since 07/08/22
3-Month
1.59 +85.53%
on 07/14/22
3.00 -1.67%
on 08/09/22
+0.20 (+7.27%)
since 05/09/22
52-Week
1.59 +85.53%
on 07/14/22
4.69 -37.10%
on 08/10/21
-1.70 (-36.56%)
since 08/09/21

Most Recent Stories

More News
Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022

Results include first U.S. revenue from Gleolan, full commercial launch expected in fiscal Q2 Treosulfan NDA resubmitted to the FDA, regulatory...

MDP.TO : 2.95 (+18.00%)
MEDXF : 2.2400 (+14.87%)
Medexus Schedules First Quarter 2023 Conference Call

TORONTO and CHICAGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at...

MDP.TO : 2.95 (+18.00%)
MEDXF : 2.2400 (+14.87%)
Treosulfan NDA Resubmitted to FDA

FDA decision expected within six months of acceptancePivotal phase 3 clinical trial of treosulfan met primary endpoint and key secondary endpoints TORONTO...

MDP.TO : 2.95 (+18.00%)
MEDXF : 2.2400 (+14.87%)
Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)

Management to host conference call at 8:00 AM Eastern Time on Thursday, June 23, 2022...

MDP.TO : 2.95 (+18.00%)
MEDXF : 2.2400 (+14.87%)
Medexus Schedules Fourth Quarter and Fiscal Year 2022 Conference Call

TORONTO and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at...

MDP.TO : 2.95 (+18.00%)
MEDXF : 2.2400 (+14.87%)
Stocks in play: Medexus Pharmaceuticals

Today announced that the American Journal of Hematology has accepted for publication the final study ...

MDP.TO : 2.95 (+18.00%)
Treosulfan Pivotal Study Results Published

Study’s primary endpoint and key secondary endpoints were met Study found event-free survival and overall survival superior after treosulfan compared to...

MDP.TO : 2.95 (+18.00%)
MEDXF : 2.2400 (+14.87%)
Toronto Stock Exchange, Medexus Pharmaceuticals, The View From The C-Suite

/CNW/ - Ken D'Entremont, Chief Executive Officer, Medexus Pharmaceuticals (Medexus) (TSX: MDP) shares his Company's story in an interview with TMX Group. The...

MDP.TO : 2.95 (+18.00%)
Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA

TORONTO and CHICAGO, May 24, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, a strategic...

MDP.TO : 2.95 (+18.00%)
MEDXF : 2.2400 (+14.87%)
Stocks in play: Medexus Pharmaceuticals

And medac, a strategic partner of Medexus, are pleased to announce that medac has resubmitted its New ...

MDP.TO : 2.95 (+18.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 3.50
2nd Resistance Point 3.25
1st Resistance Point 3.10
Last Price 2.95
1st Support Level 2.70
2nd Support Level 2.45
3rd Support Level 2.30

See More

52-Week High 4.69
Fibonacci 61.8% 3.51
Fibonacci 50% 3.14
Last Price 2.95
Fibonacci 38.2% 2.77
52-Week Low 1.59

See More

Business Summary

Medexus Pharmaceuticals Inc is a specialty pharmaceutical company. It is focused on auto-immune and pediatric diseases in the USA and Canada. The company's only reportable segment is the products sold and the marketing services offered to the pharmaceutical industry. Geographically, it derives a majority...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar